| Literature DB >> 27936208 |
Miriam Ayuso1, Almudena Fernández2, Yolanda Núñez2, Rita Benítez2, Beatriz Isabel1, Ana I Fernández2, Ana I Rey1, Antonio González-Bulnes3, Juan F Medrano4, Ángela Cánovas4, Clemente J López-Bote1, Cristina Óvilo2.
Abstract
Iberian pig production includes purebred (IB) and Duroc-crossbred (IBxDU) pigs, which show important differences in growth, fattening and tissue composition. This experiment was conducted to investigate the effects of genetic type and muscle (Longissimus dorsi (LD) vs Biceps femoris (BF)) on gene expression and transcriptional regulation at two developmental stages. Nine IB and 10 IBxDU piglets were slaughtered at birth, and seven IB and 10 IBxDU at four months of age (growing period). Carcass traits and LD intramuscular fat (IMF) content were measured. Muscle transcriptome was analyzed on LD samples with RNA-Seq technology. Carcasses were smaller in IB than in IBxDU neonates (p < 0.001), while growing IB pigs showed greater IMF content (p < 0.05). Gene expression was affected (p < 0.01 and Fold change > 1.5) by the developmental stage (5,812 genes), muscle type (135 genes), and genetic type (261 genes at birth and 113 at growth). Newborns transcriptome reflected a highly proliferative developmental stage, while older pigs showed upregulation of catabolic and muscle functioning processes. Regarding the genetic type effect, IBxDU newborns showed enrichment of gene pathways involved in muscle growth, in agreement with the higher prenatal growth observed in these pigs. However, IB growing pigs showed enrichment of pathways involved in protein deposition and cellular growth, supporting the compensatory gain experienced by IB pigs during this period. Moreover, newborn and growing IB pigs showed more active glucose and lipid metabolism than IBxDU pigs. Moreover, LD muscle seems to have more active muscular and cell growth, while BF points towards lipid metabolism and fat deposition. Several regulators controlling transcriptome changes in both genotypes were identified across muscles and ages (SIM1, PVALB, MEFs, TCF7L2 or FOXO1), being strong candidate genes to drive expression and thus, phenotypic differences between IB and IBxDU pigs. Many of the identified regulators were known to be involved in muscle and adipose tissues development, but others not previously associated with pig muscle growth were also identified, as PVALB, KLF1 or IRF2. The present study discloses potential molecular mechanisms underlying phenotypic differences observed between IB and IBxDU pigs and highlights candidate genes implicated in these molecular mechanisms.Entities:
Mesh:
Year: 2016 PMID: 27936208 PMCID: PMC5148031 DOI: 10.1371/journal.pone.0167858
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Differentially expressed (DE) genes as affected by the three studied main effects.
| Total DE genes | Upregulated genes | ||
|---|---|---|---|
| Birth | four months | ||
| Developmental stage effect (LD) | 5812 | 3290 | 2522 |
| IBxDU | IB | ||
| Genotype effect at birth (LD) | 261 | 131 | 130 |
| Genotype effect at four months (LD) | 113 | 25 | 88 |
| BF | LD | ||
| Muscle effect (birth) | 135 | 52 | 83 |
1 IBxDU = Iberian x Duroc crossbred pigs
2 IB = Purebred Iberian pigs
3 BF = Biceps femoris muscle
4 LD = Longissimus dorsi muscle
Effect of genotype, developmental stage and their interaction on phenotype of pure and crossbred Iberian pigs.
| Genetic type (GT) | Stage | GT*Stage | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Birth | Growing | |||||||||
| Carcass traits | IBxDU | IB | SEM | p-value | IBxDU | IB | SEM | p-value | p-value | p-value |
| Live weight | 1.77 | 1.21 | 0.07 | < .001 | 68.60 | 59.40 | 2.41 | 0.084 | < .001 | 0.054 |
| Carcass weight | 1.41 | 0.96 | 0.05 | < .001 | 56.22 | 48.60 | 2.17 | 0.109 | < .001 | 0.074 |
| Carcass length | 40.20 | 35.50 | 0.54 | < .001 | 121.11 | 116.17 | 1.54 | 0.140 | < .001 | 0.936 |
| Thorax circumference | 25.15 | 22.06 | 0.39 | 0.001 | 89.17 | 86.00 | 1.11 | 0.186 | < .001 | 0.974 |
| Abdomen circumference | 18.90 | 17.28 | 0.38 | 0.049 | 77.28 | 78.17 | 1.21 | 0.724 | < .001 | 0.288 |
| Ham weight | 0.16 | 0.11 | 0.01 | < .001 | 7.56 | 6.23 | 0.29 | 0.040 | < .001 | 0.017 |
| Ham length | 7.45 | 6.33 | 0.14 | < .001 | 25.89 | 24.33 | 0.36 | 0.052 | < .001 | 0.541 |
| Ham circumference | 12.55 | 10.89 | 0.23 | 0.002 | 67.83 | 59.42 | 1.74 | 0.034 | < .001 | 0.040 |
| Lipid and glucose metabolism-related plasma indicators | ||||||||||
| Cholesterol | 62.2 | 102.4 | 5.60 | 0.003 | 107.6 | 95.1 | 3.86 | 0.136 | 0.144 | 0.031 |
| LDL | 42.2 | 45.8 | 4.40 | 0.449 | 67.4 | 61.5 | 2.58 | 0.280 | 0.002 | 0.431 |
| HDL | 22.4 | 41.2 | 4.25 | 0.018 | 30.2 | 24.0 | 2.93 | 0.313 | 0.452 | 0.049 |
| TG | 30.0 | 76.7 | 5.11 | < .001 | 46.4 | 53.7 | 4.03 | 0.439 | 0.354 | 0.026 |
| Fructosamine | 169.7 | 133.7 | 10.37 | 0.101 | 221.3 | 228.0 | 8.05 | 0.691 | < .0001 | 0.135 |
| Glucose | 132.4 | 123.4 | 10.80 | 0.684 | 107.8 | 92.5 | 2.91 | 0.023 | 0.036 | 0.804 |
| IMF | 2.16 | 2.32 | 0.50 | 0.317 | 2.87 | 4.05 | 0.20 | 0.026 | < .0001 | 0.655 |
| C14:0 | 2.77 | 2.56 | 0.12 | 0.406 | 1.14 | 1.32 | 0.08 | 0.295 | < .0001 | 0.230 |
| C15:1 | 1.51 | 1.26 | 0.09 | 0.171 | 0.60 | 0.33 | 0.04 | 0.026 | < .0001 | 0.743 |
| C16:0 | 26.29 | 26.12 | 0.18 | 0.655 | 24.56 | 25.44 | 0.39 | 0.114 | 0.001 | 0.072 |
| C16:1 n-9 | 2.13 | 2.03 | 0.05 | 0.547 | 0.20 | 0.27 | 0.02 | 0.099 | < .0001 | 0.232 |
| C16:1 n-7 | 5.93 | 5.40 | 0.22 | 0.234 | 3.20 | 3.34 | 0.13 | 0.938 | < .0001 | 0.357 |
| C17:0 | 1.78 | 1.50 | 0.07 | 0.064 | 0.47 | 0.32 | 0.03 | 0.039 | < .0001 | 0.197 |
| C17:1 | 0.94 | 0.88 | 0.05 | 0.564 | 0.46 | 0.31 | 0.03 | 0.042 | < .0001 | 0.862 |
| C18:0 | 10.62 | 9.43 | 0.32 | 0.083 | 12.91 | 12.69 | 0.23 | 0.787 | < .0001 | 0.130 |
| C18:1 n-9 | 24.06 | 26.61 | 0.80 | 0.129 | 41.39 | 42.42 | 0.49 | 0.373 | < .0001 | 0.085 |
| C18:1 n-7 | 6.34 | 5.82 | 0.21 | 0.235 | 2.67 | 2.21 | 0.13 | 0.051 | < .0001 | 0.623 |
| C18:2 n-6 | 7.00 | 8.76 | 0.56 | 0.132 | 7.32 | 5.36 | 0.32 | 0.020 | 0.040 | 0.022 |
| C18:3 n-3 | 0.28 | 0.25 | 0.02 | 0.351 | 0.18 | 0.18 | 0.01 | 0.839 | 0.001 | 0.370 |
| C18:4 n-3 | 0.13 | 0.17 | 0.02 | 0.351 | 0.08 | 0.08 | 0.00 | 0.347 | 0.019 | 0.222 |
| C20:0 | 0.36 | 0.27 | 0.04 | 0.320 | 0.20 | 0.19 | 0.01 | 0.963 | 0.031 | 0.532 |
| C20:1 n-9 | 0.63 | 0.60 | 0.05 | 0.786 | 0.77 | 0.78 | 0.02 | 0.635 | 0.007 | 0.957 |
| C20:2 n-6 | 0.32 | 0.33 | 0.06 | 0.913 | 0.61 | 0.45 | 0.04 | 0.040 | 0.024 | 0.187 |
| C20:3 n-6 | 0.63 | 0.52 | 0.02 | 0.017 | 0.25 | 0.23 | 0.02 | 0.525 | < .0001 | 0.064 |
| C20:4 n-6 | 5.65 | 4.97 | 0.27 | 0.221 | 2.02 | 1.18 | 0.11 | 0.007 | < .0001 | 0.578 |
| C22:4 n-6 | 1.07 | 0.91 | 0.05 | 0.175 | 0.43 | 0.54 | 0.04 | 0.192 | < .0001 | 0.048 |
| C22:5 n-3 | 0.36 | 0.33 | 0.01 | 0.254 | 0.34 | 0.85 | 0.04 | < .0001 | < .0001 | < .0001 |
| C22:6 n-3 | 0.31 | 0.26 | 0.04 | 0.544 | 0.40 | 0.99 | 0.11 | 0.020 | 0.003 | 0.012 |
| ∑SFA | 42.57 | 40.46 | 0.54 | 0.068 | 39.32 | 40.13 | 0.55 | 0.179 | 0.009 | 0.012 |
| ∑MUFA | 41.41 | 42.82 | 0.50 | 0.174 | 49.50 | 49.01 | 0.64 | 0.419 | < .0001 | 0.108 |
| ∑PUFA | 16.02 | 16.72 | 0.44 | 0.441 | 11.73 | 9.71 | 0.50 | 0.102 | < .0001 | 0.284 |
| UI | 91.19 | 91.79 | 0.44 | 0.441 | 79.37 | 81.39 | 1.58 | 0.752 | < .0001 | 0.968 |
| ∑n-3 | 1.35 | 1.22 | 0.91 | 0.746 | 1.00 | 2.10 | 0.16 | 0.004 | 0.198 | 0.001 |
| ∑n-6 | 14.67 | 15.50 | 0.07 | 0.324 | 10.73 | 7.65 | 0.47 | 0.013 | < .0001 | 0.051 |
| ∑n-6/∑n-3 | 11.61 | 12.88 | 0.42 | 0.344 | 14.31 | 3.89 | 1.22 | 0.003 | 0.043 | < .0001 |
1 IBxDU = Iberian x Duroc crossbred pigs (n = 10)
2 IB = Purebred Iberian pigs (n = 9)
3 SEM = Standard error of the mean
4 IBxDU = Iberian x Duroc crossbred pigs (n = 10)
5 IB = Purebred Iberian pigs (n = 7)
6 LDL = Low density lipoproteins
7 HDL = High density lipoproteins
8 TG = Triglycerides
9 IMF = Intramuscular fat
10 ΣSFA = Sum of saturated fatty acids
11 ΣMUFA = Sum of monounsaturated fatty acids
12 ΣPUFA = Sum of polyunsaturated fatty acids
13 UI = Unsaturation index = 1 × (% monoenoics) +2 × (% dienoics) +3 × (% trienoics) +4 × (% tetraenoics) +5 × (% pentaenoics) +6 × (% hexaenoics)
14 Σn3 = Sum of n-3 fatty acids
15 Σn6 = Sum of n-6 fatty acids
Longissimus dorsi (LD) and Biceps femoris (BF) muscle characteristics of pure and Duroc-crossbred Iberian piglets at birth.
| Mean | p-value | ||||||
|---|---|---|---|---|---|---|---|
| Muscle | IBxDU | IB | SEM | Genetic type (GT) | Muscle | GT*Muscle | |
| ∑SFA | LD | 42.57 | 40.79 | 0.33 | 0.002 | 0.182 | 0.538 |
| BF | 41.66 | 39.91 | |||||
| ∑MUFA | LD | 41.41 | 42.73 | 0.32 | 0.114 | 0.478 | 0.653 |
| BF | 41.01 | 41.77 | |||||
| ∑PUFA | LD | 16.02 | 16.48 | 0.31 | 0.057 | 0.039 | 0.845 |
| BF | 17.34 | 18.32 | |||||
| ∑n-3 | LD | 1.35 | 1.24 | 0.04 | 0.145 | < .0001 | 0.942 |
| BF | 1.77 | 1.69 | |||||
| ∑n-6 | LD | 14.67 | 15.24 | 0.30 | 0.034 | 0.123 | 0.833 |
| BF | 15.56 | 16.63 | |||||
| ∑n-6/∑n-3 | LD | 11.61 | 12.54 | 0.36 | 0.056 | 0.002 | 0.892 |
| BF | 8.78 | 9.96 | |||||
| IMF | LD | 2.16 | 2.26 | 0.08 | 0.060 | 0.158 | 0.644 |
| BF | 1.80 | 2.16 | |||||
1 IBxDU = Iberian x Duroc crossbred pigs (n = 10)
2 IB = Purebred Iberian pigs (n = 9)
3 SEM = Standard error of the mean
4 ΣSFA = Sum of saturated fatty acids
5 ΣMUFA = Sum of monounsaturated fatty acids
6 ΣPUFA = Sum of polyunsaturated fatty acids
7 Σn3 = Sum of n-3 fatty acids
8 Σn6 = Sum of n-6 fatty acids
9 IMF = Intramuscular fat
Enriched biological functions in the set of DE genes between LD muscle from newborn and growing Iberian pigs
| Upregulated at birth | Upregulated at growing stage | ||||
|---|---|---|---|---|---|
| Enriched function | Corrected p-value | z-score | Enriched function | Corrected p-value | z-score |
| Invasion of cells | 2.66E-10 | 3.93 | Organismal death | 4.90E-23 | 6.95 |
| Size of body | 2.23E-06 | 3.58 | Growth Failure | 1.08E-04 | 4.94 |
| Transport of molecule | 1.78E-08 | 3.33 | Bleeding | 1.31E-03 | 4.93 |
| Invasion of tumor cell lines | 1.67E-06 | 3.18 | Perinatal death | 6.00E-06 | 3.92 |
| Cell movement | 1.63E-17 | 3.09 | contractility of skeletal muscle | 5.25E-04 | 3.86 |
| Cell movement of tumor cell lines | 3.06E-07 | 3.05 | Hypoplasia of organ | 2.73E-03 | 3.26 |
| Apoptosis of fibroblast cell lines | 5.99E-08 | 3.03 | Hypoplasia | 1.62E-04 | 3.15 |
| Adhesion of connective tissue cells | 1.40E-03 | 2.94 | Dysgenesis | 1.21E-04 | 3.04 |
| Cancer | 9.37E-54 | 2.94 | Congenital anomaly of musculoskeletal system | 7.19E-05 | 2.92 |
| Migration of cells | 2.73E-03 | 2.90 | Multiple congenital anomalies | 1.13E-07 | 2.91 |
| Migration of tumor cell lines | 9.70E-15 | 2.77 | Polymerization of protein | 2.01E-05 | 2.73 |
| Limb development | 1.46E-09 | 2.77 | Fibrosis | 1.06E-04 | 2.39 |
| Invasion of tumor | 5.45E-07 | 2.70 | Hypoplasia of thorax | 1.41E-03 | 2.25 |
| Proliferation of fibroblasts | 2.37E-04 | 2.59 | Autophagy | 1.84E-03 | 2.18 |
| Adhesion of tumor cell lines | 4.38E-09 | 2.58 | Anemia | 1.49E-03 | 1.84 |
| Disassembly of filaments | 5.25E-07 | 2.56 | Mass of muscle | 1.99E-14 | 1.77 |
| Synthesis of DNA | 4.31E-05 | 2.56 | Adhesion of extracellular matrix | 1.75E-05 | 1.73 |
| Invasion of breast cancer cell lines | 9.33E-05 | 2.56 | Autosomal recessive disease | 1.61E-03 | 1.72 |
| Synthesis of carbohydrate | 2.27E-03 | 2.52 | Mass of skeletal muscle | 2.14E-07 | 1.69 |
| Tumorogenesis of tissue | 2.43E-04 | 2.46 | Blood vessel defect | 1.28E-03 | 1.56 |
| Neoplasia of cells | 1.28E-03 | 2.45 | Systemic autoinmune syndrome | 7.10E-05 | 1.53 |
| Invasion of tumor cells | 1.95E-03 | 2.40 | Dwarfism | 2.68E-08 | 1.46 |
| Organization of cytoplasm | 1.68E-47 | 2.36 | Abnormal bone density | 2.78E-03 | 1.45 |
| Metabolism of carbohydrate | 3.24E-04 | 2.36 | Dysplasia of skeleton | 6.50E-13 | 1.38 |
| Endocytosis | 1.21E-05 | 2.33 | Aneurysm | 3.42E-18 | 1.38 |
| Proliferation of neuronal cells | 2.23E-03 | 2.30 | Vascular tumor | 1.09E-20 | 1.33 |
| Organization of cytoskeleton | 3.35E-16 | 2.28 | Hemangioma | 4.13E-04 | 1.33 |
| Development of central nervoussystem | 4.95E-06 | 2.26 | Hypertension | 2.16E-03 | 1.33 |
| Development of body trunk | 3.87E-05 | 2.22 | Hypoglycemia | 3.79E-05 | 1.24 |
| Outgrowth of cells | 5.94E-07 | 2.19 | Adhesion of cell-associated matrix | 1.86E-03 | 1.19 |
| Neoplasia of epitelial tissue | 2.20E-15 | 2.18 | Ulcer | 1.11E-04 | 1.13 |
| Formation of celular protrusions | 1.88E-04 | 2.18 | Chronic inflammatory disorder | 1.15E-03 | 1.06 |
| Microtubule dynamics | 1.50E-08 | 2.16 | Replication of virus | 9.27E-05 | 1.01 |
| Behavior | 6.31E-04 | 2.12 | Quantity of muscle cells | 7.41E-04 | 0.99 |
| Cell death of fibroblasts | 1.05E-47 | 2.11 | Mass of hind limb muscle | 7.62E-09 | 0.91 |
| Proliferation of cells | 2.64E-08 | 2.10 | Function of muscle | 1.35E-06 | 0.89 |
| Invasion of malignant tumor | 1.02E-13 | 2.10 | Breast or ovarían cancer | 3.28E-13 | 0.86 |
| Development of cardiovascular system | 3.94E-04 | 2.06 | Quantity of muscle | 5.41E-05 | 0.86 |
| Cell surface receptor linked signal transduction | 3.70E-04 | 2.01 | Abdominal aortic aneurysm | 5.06E-04 | 0.83 |
| Angiogenesis | 6.11E-37 | 2.00 | Stabilization of microtubules | 1.79E-03 | 0.82 |
1 Z-score: Predicted activation status of biological function. The higher the value, the more activated the functions is predicted to be.
Enriched pathways in the set of DE genes conditional on genetic type at birth and at growing.
| Birth | Growing | ||||
|---|---|---|---|---|---|
| IB | p-value | Corrected p-value | IB | p-value | Corrected p-value |
| Role of IL-17A in Psoriasis | 2.83E-05 | 6.60E+00 | Serine Biosynthesis | 5.57E-09 | 8.08E-08 |
| PI3K Signaling in B Lymphocytes | 6.56E-05 | 6.60E+00 | Superpathway of Serine and Glycine Biosynthesis I | 1.29E-08 | 1.42E-07 |
| ERK5 Signaling | 7.65E-05 | 6.60E+00 | Glutathione-mediated Detoxification | 1.05E-04 | 5.14E+00 |
| Melatonin Degradation III | 1.87E-04 | 6.60E+00 | LPS/IL-1 Mediated Inhibition of RXR Function | 1.09E-04 | 5.14E+00 |
| Glutamine Biosynthesis I | 1.87E-04 | 6.60E+00 | Alanine Degradation III | 3.01E-04 | 5.14E+00 |
| NRF2-mediated Oxidative Stress Response | 6.00E-04 | 4.03E+01 | Alanine Biosynthesis II | 3.01E-04 | 5.14E+00 |
| IL-8 Signaling | 6.92E-04 | 4.03E+01 | Cell Cycle: G1/S Checkpoint Regulation | 2.02E-03 | 5.14E+00 |
| April Mediated Signaling | 1.47E-03 | 4.03E+01 | Cyclins and Cell Cycle Regulation | 4.96E-03 | 5.14E+00 |
| Trehalose Degradation II (Trehalase) | 1.81E-03 | 4.09E+01 | Glucose and Glucose-1-phosphate Degradation | 6.29E-03 | 5.14E+00 |
| B Cell Activating Factor Signaling | 1.81E-03 | 4.09E+01 | p53 Signaling | 1.62E-02 | 5.14E+00 |
| LXR/RXR Activation | 2.80E-03 | 4.09E+01 | Leukotriene Biosynthesis | 3.71E-02 | 5.14E+00 |
| Atherosclerosis Signaling | 3.13E-03 | 6.28E+01 | LXR/RXR Activation | 4.97E-02 | 5.14E+00 |
| TNFR1 Signaling | 4.68E-03 | 6.28E+01 | |||
| Wnt/Ca+ pathway | 9.09E-03 | 6.57E+01 | |||
| Glucocorticoid Receptor Signaling | 1.17E-02 | 6.57E+01 | |||
| GDP-glucose Biosynthesis | 1.52E-02 | 2.44E+02 | |||
| Glucose and Glucose-1-phosphate Degradation | 2.27E-02 | 3.24E+02 | |||
| Growth Hormone Signaling | 2.61E-02 | 4.33E+02 | |||
| Melatonin Signaling | 2.80E-02 | 4.41E+02 | |||
| UDP-N-acetyl-D-galactosamine Biosynthesis II | 3.22E-02 | 4.41E+02 | |||
| Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis | 3.99E-02 | 4.41E+02 | |||
| Production of Nitric Oxide and Reactive Oxygen Species in Macrophages | 4.97E-02 | 4.41E+02 | |||
| IBxDU | p-value | Corrected p-value | IBxDU | p-value | Corrected p-value |
| AldosteroneSignaling in EpithelialCells | 1.11E-10 | 1.02E-09 | Acute Phase Response Signaling | 3.90E-05 | 1.73E-02 |
| ProteinUbiquitinationPathway | 1.71E-09 | 2.09E-08 | Retinoate Biosynthesis II | 9.68E-05 | 1.73E-02 |
| Unfoldedprotein response | 5.94E-08 | 1.64E-06 | Bupropion Degradation | 1.03E-03 | 4.62E-02 |
| eNOSSignaling | 6.94E-06 | 1.47E-03 | Acetone Degradation I (to Methylglyoxal) | 1.47E-03 | 4.62E-02 |
| EndoplasmicReticulum Stress Pathway | 1.79E-04 | 1.91E-01 | Retinoate Biosynthesis I | 2.02E-03 | 4.62E-02 |
| PyrimidineRibonucleotidesInterconversion | 4.74E-04 | 1.91E-01 | Retinol Biosynthesis | 2.80E-03 | 4.62E-02 |
| Glucocorticoid Receptor Signaling | 5.45E-04 | 1.91E-01 | Estrogen Biosynthesis | 3.51E-03 | 4.62E-02 |
| PyrimidineRibonucleotides De Novo Biosynthesis | 6.29E-04 | 1.91E-01 | Nicotine Degradation III | 5.26E-03 | 4.62E-02 |
| NeuregulinSignaling | 6.29E-04 | 1.91E-01 | Melatonin Degradation I | 8.03E-03 | 4.62E-02 |
| Role of p14/p19ARF in Tumor Suppression | 7.27E-04 | 1.91E-01 | Nicotine Degradation II | 9.68E-03 | 4.62E-02 |
| SpermineBiosynthesis | 8.41E-04 | 1.91E-01 | IL-17 Signaling | 1.10E-02 | 4.62E-02 |
| AlanineDegradation III | 8.41E-04 | 1.91E-01 | GABA Receptor Signaling | 1.10E-02 | 4.62E-02 |
| AlanineBiosynthesis II | 8.41E-04 | 1.91E-01 | Superpathway of Melatonin Degradation | 1.33E-02 | 4.62E-02 |
| Hepatic Fibrosis / HepaticStellateCellActivation | 2.02E-03 | 5.58E-01 | IL-6 Signaling | 4.29E-02 | 4.62E-02 |
| Spermidine Biosynthesis I | 2.02E-03 | 5.58E-01 | |||
| PI3K/AKT Signaling | 4.96E-03 | 1.94E+00 | |||
| Serine Biosynthesis | 7.10E-03 | 2.93E+00 | |||
| Thioredoxin Pathway | 1.17E-02 | 4.26E+00 | |||
| Aryl Hydrocarbon Receptor Signaling | 1.17E-02 | 4.26E+00 | |||
| Epithelial Adherens Junction Signaling | 1.62E-02 | 5.32E+00 | |||
| Superpathway of Serine and Glycine Biosynthesis I | 1.85E-02 | 5.32E+00 | |||
| PCP pathway | 2.27E-02 | 6.37E+00 | |||
| Hypoxia Signaling in the Cardiovascular System | 2.80E-02 | 6.37E+00 | |||
| Mitotic Roles of Polo-Like Kinase | 3.00E-02 | 6.37E+00 | |||
| Tight Junction Signaling | 4.62E-02 | 1.03E+01 | |||
1 IB = Purebred Iberian pigs
2 IBxDU = Iberian x Duroc crossbred pigs
Enriched biological functions in the set of DE genes conditional on genetic type, at birth and at growth.
| Birth | Growth | ||||||
|---|---|---|---|---|---|---|---|
| IB | |||||||
| Function | P-value | Corrected p-value | z-score | Function | p-Value | Corrected p-value | z-score |
| Cell death of tumor cell lines | 2.49E-06 | 5.45E-04 | -2.82 | Size of body | 7.37E-03 | 4.89E-02 | -2.356 |
| Apoptosis | 2.05E-09 | 4.03E-06 | -2.60 | Quantity of connective tissue | 3.22E-03 | 3.47E-02 | -1.987 |
| Apoptosis of tumor cell lines | 1.16E-07 | 1.15E-04 | -2.57 | Lesion formation | 2.50E-04 | 2.92E-02 | -1.353 |
| Degradation of protein | 2.63E-03 | 4.00E-02 | -2.57 | Concentration of lipid | 2.45E-04 | 2.92E-02 | -1.137 |
| Necrosis | 3.15E-07 | 2.48E-04 | -2.54 | Concentration of fatty acid | 6.70E-03 | 4.48E-02 | -1.091 |
| Cell death | 1.46E-10 | 5.75E-07 | -2.49 | Activation of macrophages | 1.26E-02 | 5.59E-02 | -1.091 |
| Inflammatory response | 2.21E-03 | 3.55E-02 | -2.47 | Size of lesion | 2.94E-03 | 3.36E-02 | -0.747 |
| Accumulation of myeloid cells | 7.89E-03 | 5.22E-02 | -2.42 | Size of bone | 1.20E-02 | 5.44E-02 | -0.682 |
| Colony formation of tumor cell lines | 1.49E-03 | 2.79E-02 | -2.39 | Proliferation of cells | 1.24E-02 | 3.36E-02 | -0.578 |
| Proliferation of tumor cells | 7.12E-03 | 5.22E-02 | -2.35 | Concentration of triacylglycerol | 1.45E-03 | 4.93E-02 | -0.412 |
| Synthesis of reactive oxygen species | 2.91E-04 | 1.00E-02 | -2.35 | Quantity of reactive oxygen species | 8.63E-03 | 4.89E-02 | -0.283 |
| Colony formation of cells | 3.24E-04 | 1.07E-02 | -2.30 | ||||
| Accumulation of neutrophils | 5.54E-04 | 1.45E-02 | -2.20 | ||||
| Killing of bacteria | 3.49E-04 | 1.12E-02 | -2.19 | ||||
| Generation of reactive oxygen species | 9.50E-04 | 2.04E-02 | -2.13 | ||||
| Atrophy of muscle | 2.97E-03 | 4.19E-02 | -2.11 | ||||
| Differentiation of connectivetissue | 1.24E-03 | 2.46E-02 | -2.05 | ||||
| Metastasis of melanoma celllines | 1.47E-04 | 6.57E-03 | -2.00 | ||||
| IBxDU | |||||||
| Quantity of erythroid progenitor cells | 2.14E-03 | 3.55E-02 | 2.19 | Organismal death | 5.13E-03 | 4.13E-02 | 2.615 |
| Cytolysis | 2.99E-05 | 2.73E-03 | 2.18 | Necrosis of epitelial tissue | 3.53E-03 | 3.72E-02 | 1.450 |
| Engulfment of cells | 3.67E-03 | 4.74E-02 | 2.05 | Metabolism of reactive oxygen species | 1.09E-02 | 5.44E-02 | 1.261 |
| Morphology of cells | 7.37E-05 | 4.53E-03 | 2.05 | Neuronal cell death | 8.40E-03 | 4.93E-02 | 1.202 |
| Mean corpuscular hemoglobin concentration | 4.14E-04 | 1.22E-02 | 2.00 | Transport of molecule | 1.21E-02 | 5.44E-02 | 1.154 |
| Cellviability of tumor celllines | 4.72E-03 | 5.22E-02 | 1.99 | Oxidation of lipid | 2.74E-04 | 3.02E-02 | 1.127 |
| Extension of neurites | 3.92E-03 | 4.94E-02 | 1.98 | Celldeath of epithelialcells | 4.45E-03 | 4.13E-02 | 1.118 |
| Cell viability | 8.69E-05 | 4.96E-03 | 1.97 | Colonyformation of tumor celllines | 1.39E-02 | 5.96E-02 | 1.103 |
| Quantity of reticulocytes | 1.99E-03 | 3.36E-02 | 1.96 | Hydrolysis of triacylglycerol | 7.45E-06 | 7.39E-03 | 1.091 |
| Cytosis | 5.19E-03 | 5.22E-02 | 1.94 | Morbidity or mortality | 1.15E-02 | 5.44E-02 | 1.067 |
| Cell survival | 3.18E-05 | 2.78E-03 | 1.86 | Inflammation of body cavity | 6.07E-03 | 4.13E-02 | 1.000 |
| Anemia | 1.58E-05 | 1.81E-03 | 1.80 | Cell death | 5.47E-04 | 3.36E-02 | 0.980 |
| Phagocytosis of cells | 1.49E-03 | 2.79E-02 | 1.80 | Cancer | 7.95E-03 | 4.93E-02 | 0.825 |
| Hyperplasia of epidermis | 8.90E-05 | 5.00E-03 | 1.71 | Hypertrophy | 1.08E-02 | 5.44E-02 | 0.808 |
| Size of cells | 8.43E-03 | 5.22E-02 | 1.60 | Cell death of central nervous system cells | 7.74E-03 | 4.93E-02 | 0.791 |
| Binding of cells | 2.60e-03 | 3.97E-02 | 1.49 | Mineralization of cells | 1.06E-04 | 1.81E-02 | 0.762 |
| Binding of granulocytes | 2.43e-04 | 8.61E-03 | 1.47 | Apoptosis | 3.24E-03 | 3.47E-02 | 0.731 |
| Mass of muscle | 1.96e-03 | 4.53E-02 | 1.38 | Inflammation of organ | 2.73E-03 | 3.36E-02 | 0.712 |
1 IB = Purebred Iberian pigs
2 Z-score: Predicted activation status of biological function. The higher the value, the more activated the functions is predicted to be.
3 IBxDU = Iberian x Duroc crossbred pigs
Fig 1Venn diagram showing common differentially expressed genes across studied conditions.
Developmental stage, the biggest studied effect, shows several common differentially expressed genes with other effects, while expression of any gene was affected by the three studied effects.
Fig 2Enriched biological functions related to body growth in growing Iberian (IB) pigs.
The network generated by IPA software shows enriched biological functions in IB pigs (blue color) and genes predicted to be involved in enrichment of these functions. The activation of cell proliferation and body size in growing IB pigs might be related to a compensatory growth occurring in those pigs when compared to crossbred (IBxDU) pigs during the early growing period.
Fig 3Enriched biological functions related to growth and development in newborn Iberian (IB) piglets.
The activation of muscle atrophy and the upregulation of genes involved in protein metabolism and degradation in IB pigs suggests a more active protein turnover in these pigs when compared to crossbred (IBxDU) pigs. Functions associated with animal growth were also enriched in IB newborn pigs.
Fig 4Enriched biological functions related to lipid metabolism in growing Iberian (IB) pigs.
The network generated by IPA software shows metabolism-related enriched biological functions in IB pigs. Concentration of lipid seems to be a more active process in IB pigs, in agreement with phenotypic differences observed in loin intramuscular fat content.
Fig 5Adipogenesis pathway.
Several transcription factor identified in the regulators study and one gene upregulated in Iberian pigs are involved in the adipogenesis pathway, most of them regulate PPARg expression or activation.
Fig 6Enriched biological functions in Biceps femoris (BF) muscle.
The network generated by IPA software shows enriched biological functions in BF muscle, suggesting that lipid metabolism is more active in BF when compared to Longissimus dorsi muscle.